Future growth expectations in sales/revenue/volumes?

Mid-teens revenue growth expected for FY '26, with cautious optimism due to a high current base and industry growth of 10-11%. Volume growth anticipated around 14%, aligned closely with revenue growth due to tiered pricing structure, with no material price increases expected. Franchisee network set to expand with plans to add 1,500 to 2,000 new franchise partners annually, supporting growth over next 3-5 years. Partnership business growing strongly, including health tech and corporate/insurance segments, aiding volume and revenue expansion. Continued focus on specialized test menu expa

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth guidance for FY '26 is mid-teens percentage, reflecting cautious optimism due to a high base and competitive pressure. Volume growth is expected around 14%, with revenue growth around 20% for recent years; for FY '26, mid-teen revenue growth is targeted. EBITDA margin target for FY '26 is around 31% normalized, similar to FY '25 levels. Operating leverage benefits are expected to sustain profitability, with investments continuing in specialized tests and new labs. Smaller, consistent acquisitions (in the range of INR15-20 crores) will be selective and not materially impact earni

Any current/future capex/capital investment/strategic investment?

For FY '25, capex was roughly INR 40-50 crores annually. The company has sufficient cash flow to manage capex and acquisitions without stress. No large amount has been set aside for acquisitions in FY '26; expected deployment around INR 15-20 crores focused on weaker geographies (Gujarat, Rajasthan, Northeast). The company pursues a “string of pearls” acquisition strategy—small, focused acquisitions rather than large deals, due to management bandwidth considerations. Capital investment in Nueclear centers is not planned currently, as a new center setup costs around INR 10 crores; focus remains

Any current/future new fundraising through debt or equity?

No significant new fundraising through debt or equity is planned currently. The company is a zero-debt entity with strong operating cash flow generation (INR191 crores in FY '25). Annual capex is relatively low (INR40-50 crores), easily funded by internal cash flows. The company maintains around INR80+ crores in cash reserves for contingencies and future investments. Acquisitions are expected to be small (around INR15-20 crores for FY '25) in focused geographies; these will be funded through cash flows. The company prefers "string of pearls" smaller acquisitions rather than large-scale buyouts

IN US

Sale is live|00:00:00left today

Thyrocare Technologies LtdQ1 FY25Healthcare Services

Thyrocare Technologies Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹546P/E: 43.9Market Cap: ₹7.4K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Mid-teens revenue growth expected for FY '26, with cautious optimism due to a high current base and industry growth of 10-11%.
→Volume growth anticipated around 14%, aligned closely with revenue growth due to tiered pricing structure, with no material price increases expected.
→Franchisee network set to expand with plans to add 1,500 to 2,000 new franchise partners annually, supporting growth over next 3-5 years.
→Partnership business growing strongly, including health tech and corporate/insurance segments, aiding volume and revenue expansion.
→Continued focus on specialized test menu expansion, including allergy and genomics, poised to drive higher realization and growth.
→Operating leverage and quality improvements expected to sustain margins, with a target to maintain around 31% normalized EBITDA.
→Imaging and Nueclear businesses to sustain or modestly grow, with no significant new capital expenditure planned in Nueclear centers.

Margin guidance

Category 3

→Revenue growth guidance for FY '26 is mid-teens percentage, reflecting cautious optimism due to a high base and competitive pressure.
→Volume growth is expected around 14%, with revenue growth around 20% for recent years; for FY '26, mid-teen revenue growth is targeted.
→EBITDA margin target for FY '26 is around 31% normalized, similar to FY '25 levels.
→Operating leverage benefits are expected to sustain profitability, with investments continuing in specialized tests and new labs.
→Smaller, consistent acquisitions (in the range of INR15-20 crores) will be selective and not materially impact earnings.
→Franchisee addition is robust, targeting 1,500-2,000 new franchise partners annually for the next 3-5 years, supporting volume growth.
→Effective tax rate expected at 28-29%.
→Earnings growth is expected to continue driven by volume growth, operating leverage, and price realization through tiered pricing.

3 more insights locked — sign up free to unlock

Fundraise plans

→No significant new fundraising through debt or equity is planned currently.
→The company is a zero-debt entity with strong operating cash flow generation (INR191 crores in FY '25).
→Annual capex is relatively low (INR40-50 crores), easily funded by internal cash flows.
→The company maintains around INR80+ crores in cash reserves for contingencies and future investments.
→Acquisitions are expected to be small (around INR15-20 crores for FY '25) in focused geographies; these will be funded through cash flows.
→The company prefers "string of pearls" smaller acquisitions rather than large-scale buyouts, managing capital deployment cautiously.
→Dividend payments are substantial but balanced with cash flow needs; no indication of raising capital to fund dividends or operations.

Order book

The transcript does not explicitly mention the company's current or expected orderbook or pending orders. However, relevant insights related to growth and partnerships include: - Thyrocare is at a run rate of nearly INR 60 lakhs per quarter in partnership business, expecting ~100% growth next quarter. - Currently working with about 150 partners; cautious in adding new partners but steadily growing wallet share. - Franchise network growing robustly, with 1,500 to 2,000 new franchisees targeted annually. - Expansion into new geographies through acquisitions with a moderate planned investment of INR 15-20 crores. - Strong focus on expanding both franchise and partnerships business to maintain mid-teens revenue growth. No specific details on orderbook or pending orders are disclosed.

Capex plans

Yes

→For FY '25, capex was roughly INR 40-50 crores annually.
→The company has sufficient cash flow to manage capex and acquisitions without stress.
→No large amount has been set aside for acquisitions in FY '26; expected deployment around INR 15-20 crores focused on weaker geographies (Gujarat, Rajasthan, Northeast).
→The company pursues a “string of pearls” acquisition strategy—small, focused acquisitions rather than large deals, due to management bandwidth considerations.
→Capital investment in Nueclear centers is not planned currently, as a new center setup costs around INR 10 crores; focus remains on maintaining and optimizing existing centers.
→Continuing investments planned in franchisee/partner network expansion, targeting addition of about 1,500 new franchise partners.
→Investments in new testing technologies like allergy and genomics are planned for the current year.

How does Thyrocare Technologies Ltd rank vs peers in Healthcare Services?

Pro feature

1Thyrocare Technologies Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Thyrocare Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio